Achievement of Low Disease Activity Over 52 Weeks in Patients with Active Axial Spondyloarthritis on Bimekizumab Treatment: Results from the Phase 3 Studies BE MOBILE 1 and BE MOBILE 2

Objective

To report achievement of low disease activity, as assessed by either ASDAS <2.1, BASDAI <4, or both, to Week 52 with bimekizumab across the full disease spectrum of axial spondyloarthritis in two phase 3 studies.

Background

- The recommended treatment target for axial spondyloarthritis (axSpA) is remission or low disease activity (LDA) based on Ankylosing Spondylitis Disease Activity Score (ASDAS) levels.¹
- The Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) remains commonly used in clinical practice, although limited data exist to validate cut-offs for BASDAI that would indicate remission or LDA.^{2,3}
- · Bimekizumab (BKZ) is a monoclonal IgG1 antibody that selectively inhibits interleukin (IL)-17F in addition to IL-17A.⁴
- BKZ has demonstrated consistent and sustained efficacy to Week 52 in patients with non-radiographic (nr-)axSpA and radiographic (r-)axSpA (i.e., ankylosing spondylitis), indicative of remission or LDA.^{4,5}

Methods

- The parallel BE MOBILE 1 (nr-axSpA; NCT03928704) and BE MOBILE 2 (r-axSpA; NCT03928743) studies comprised a 16-week placebo-controlled and 36-week maintenance period (Figure 1).4
- Placebo-randomised patients switched to BKZ at Week 16.
- These studies included patients with BASDAI \geq 4, but did not specify an inclusion criterion based on ASDAS levels.
- Here, we report the proportion of patients achieving LDA to Week 52, as defined by either ASDAS <2.1, BASDAI <4 or both using multiple imputation (MI) and non-responder imputation (NRI).
- The proportion and baseline characteristics of patients achieving LDA by one measure and/or the other at Week 52 are also reported using NRI.

Results

Patients

- Of the 254 patients with nr-axSpA and 332 with r-axSpA randomised, most completed the 52-week study period:
- nr-axSpA: PBO/BKZ: 85.7%; BKZ: 87.5%
- **r-axSpA:** PBO/BKZ: 91.9%; BKZ: 88.7%

Achievement of LDA

- In patients with nr-axSpA and r-axSpA, a greater proportion of BKZ vs placebo-treated patients achieved LDA at Week 16 according to ASDAS <2.1, BASDAI <4, and both (Figure 2).
- Responses, as measured by achievement of ASDAS <2.1 and/or BASDAI <4, were sustained or improved to Week 52 with BKZ treatment and approached those of BKZ-randomised patients among patients switching to BKZ from placebo at Week 16.

Comparison of ASDAS and BASDAI as Measures of LDA

- The proportion of patients achieving BASDAI <4 was generally higher compared to achievement of ASDAS <2.1, regardless of treatment arm (Figure 3).
- A larger majority of patients who achieved ASDAS <2.1 also achieved BASDAI <4 than vice versa (Figure 3).
- A higher proportion of patients who achieved both ASDAS <2.1 and BASDAI <4 were younger, male and had experienced their first symptoms of axSpA more recently compared to patients who did not achieve either (Table 1).


Conclusions

Across the full disease spectrum of axSpA, dual inhibition of IL-17A and IL-17F with bimekizumab resulted in sustained achievement of LDA vs placebo to Week 16, with the proportion of patients achieving LDA increasing to Week 52.


The larger proportion of patients achieving BASDAI <4 but not ASDAS <2.1 suggests that the latter may be a more stringent criterion for LDA. This is relevant for the consideration of bimekizumab in the context of a potential treat-to-target approach for patients with axSpA in daily practice.


Summary


Treatment with bimekizumab resulted in sustained achievement



Proportion of patients achieving ASDAS <2.1, BASDAI <4, or both, over 52 weeks (NRI and MI) Figure 2









rsity Medical Center, Leiden, The Netherlands; ³Case Western Reserve Univ To receive a copy of this poster, sca Canada; ⁶UCB Pharma, Brussels, Belgium; ⁷UCB Pharma, Monheim am Rhein, Germany; ⁸UCB Pharma, Brussels, Belgium; ⁹UCB Pharma, Slough, UK; ¹⁰NIHR Leeds Institute of Rheumatology, La Paz University Hospital, IdiPaz, Madrid, Spain. he QR code or visit len J. Ann Rheum Dis. 2018;77:3–17; ²Kwon OC. Rheumatology (Oxford). 2022;61:2369–74; ³Chen Y-H. Front Med (Lausanne). 2022;9:856654; ⁴Baraliakos X. Arthritis Rheumatol. 2022;9:856654; ⁴Baraliakos X. Arthritis Rheumatology (Oxford). 2019;78:1545–9. Author Contributions: Substantial contributions: Substantial contributions: Substantial contributions to study conception/design, or acquisition/analysis/interpretation of data: XB, SR, MM, MR, NH, CF, UM, MD, TV, HMO, VNC. Drafting of the publication; or revising it critically for important intellectual =EULAR2023 POS1106 content: XB, SR, MM, MR, NH, CF, UM, NdP, TV, HMO, VNC. Final approval of the publication: XB, SR, MM, MR, NH, CF, UM, NdP, TV, HMO, VNC. Author Disclosures: XB: Speakers bureau: AbbVie, BMS, Chugai, Eli Lilly, Galapagos, Gilead, MSD, Novartis, Pfizer and UCB Pharma; Consultancy: AbbVie, BMS, Chugai, Eli Lilly, Galapagos, Gilead, MSD, Novartis, Pfizer and UCB Pharma; Consultancy: AbbVie, BMS, Chugai, Eli Lilly, Galapagos, Gilead, MSD, Novartis, Pfizer and UCB Pharma; Consultancy: AbbVie, BMS, Chugai, Eli Lilly, Salapagos, Gilead, MSD, Novartis, Pfizer and UCB Pharma; Consultancy: AbbVie, BMS, Chugai, Eli Lilly, Novartis, Pfizer and UCB Pharma; Consultancy: AbbVie, BMS, Eli Lilly, Novartis, Pfizer and UCB Pharma; Consultancy: AbbVie, BMS, Eli Lilly, Novartis, Pfizer and UCB Pharma; Consultancy: AbbVie, BMS, Eli Lilly, Novartis, Pfizer and UCB Pharma; Consultancy: AbbVie, BMS, Eli Lilly, Novartis, Pfizer and UCB Pharma; Consultancy: AbbVie, BMS, Eli Lilly, Janssen, Novartis, Pfizer and UCB Pharma; Consultancy: AbbVie, BMS, Eli Lilly, Janssen, Novartis, Pfizer and UCB Pharma; Consultancy: AbbVie, Eli Lilly, Janssen, Novartis, Pfizer and UCB Pharma; Consultancy: AbbVie, Eli Lilly, Janssen, Novartis, Pfizer and UCB Pharma; Consultancy: AbbVie, Eli Lilly, Janssen, Novartis, Pfizer and UCB Pharma; Consultancy: AbbVie, Eli Lilly, Janssen, Novartis, Pfizer and UCB Pharma; Consultancy: AbbVie, Eli Lilly, Janssen, Novartis, Pfizer and UCB Pharma; Consultancy: AbbVie, Eli Lilly, Janssen, Novartis, Pfizer and UCB Pharma; Consultancy: AbbVie, Eli Lilly, Janssen, Novartis, Pfizer and UCB Pharma; Consultancy: AbbVie, Eli Lilly, Janssen, Novartis, Pfizer and UCB Pharma; Consultancy: AbbVie, Eli Lilly, Janssen, Moontake, MSD, Novartis, Pfizer and UCB Pharma; Consultancy: AbbVie, Eli Lilly, Janssen, MSD, Novartis, Pfizer and UCB Pharma; Consultancy: AbbVie, Eli Lilly, Janssen, MSD, Novartis, Pfizer and UCB Pharma; Consultancy: AbbVie, Eli Lilly, Janssen, MSD, Novartis, Pfizer and UCB Pharma; Research grants; Pfizer, Takeda and UC patients and their caregivers in addition to all the investigators and their teams who contributed to these studies. The authors acknowledge Celia Menckeberg PhD, UCB Pharma, for publication coordination, Hugh Osborne, PhD, Costello Medical, Cambridge, UK for medical writing and editorial assistance, and the costello Medical Creative team for design support. These studies were was funded by UCB Pharma, for publication coordination, Hugh Osborne, PhD, Costello Medical, Cambridge, UK for medical writing and editorial assistance, and the costello Medical Creative team for design support. These studies were was funded by UCB Pharma, for publication coordination, Hugh Osborne, PhD, Costello Medical, Cambridge, UK for medical writing and editorial assistance, and the costello Medical Creative team for design support. These studies were was funded by UCB Pharma, for publication coordination, Hugh Osborne, PhD, Costello Medical, Cambridge, UK for medical writing and editorial assistance, and the costello Medical Creative team for design support. These studies were was funded by UCB Pharma, for publication coordination, Hugh Osborne, PhD, Costello Medical writing and editorial assistance, and the costello Medical Creative team for design support. These studies were was funded by UCB Pharma, for publication coordination, Hugh Osborne, PhD, Costello Medical Were team for design support. Link expiration: 17 June 20

Presented at EULAR 2023 | Milan, Italy | 31 May-3 June 2023

Xenofon Baraliakos,¹ Sofia Ramiro,² Marina Magrey,³ Martin Rudwaleit,⁴ Nigil Haroon,⁵ Carmen Fleurinck,⁶ Ute Massow,⁷ Natasha de Peyrecave,⁸ Thomas Vaux,⁹ Helena Marzo-Ortega,¹⁰ Victoria Navarro-Compán¹¹

Figure 1 Study design

on MRI and/or elevated CRP [≥6 mg/L]); ^bIncluded adult patients had radiographic evidence of axSpA fulfilling both Modified New York criteria and ASAS classification criteria


Baseline characteristics of patients with nr-axSpA (BE MOBILE 1) and r-axSpA (BE MOBILE 2) who did Table 1 or did not achieve LDA at Week 52 (NRI)

		PBO/BKZ 160 mg Q4W				BKZ 160 mg Q4W													
Level of disease activity nr-axSpA (BE MOBILE 1) r-axSpA (BE MOBILE 2)		ASDAS <2.1 BASDAI <4 n=57 n=65	ASDAS <2.1 BASDAI ≥4 n=3 n=3	ASDAS ≥2.1 BASDAI <4 n=16 n=15	ASDAS ≥2.1 BASDAI ≥4 n=50 n=28	ASDAS <2.1 BASDAI <4 n=63 n=110	ASDAS <2.1 BASDAI ≥4 n=6 n=1	ASDAS ≥2.1 BASDAI <4 n=22 n=49	ASDAS ≥2.1 BASDAI ≥4 n=37 n=61										
										Age, years, mean (SD)	nr-axSpA	35.7 (10.0)	41.3 (4.7)	37.9 (11.8)	44.0 (12.6)	37.1 (10.2)	43.0 (13.6)	37.6 (10.8)	44.1 (11.4)
											r-axSpA	36.9 (11.1)	50.3 (9.1)	37.7 (11.4)	44.3 (14.8)	38.8 (11.7)	46.0 (0)	39.4 (11.1)	46.3 (12.4)
Male , n (%)	nr-axSpA	38 (66.7)	0	5 (31.3)	22 (44.0)	42 (66.7)	2 (33.3)	13 (59.1)	16 (43.2)										
	r-axSpA	48 (73.8)	1 (33.3)	11 (73.3)	20 (71.4)	80 (72.7)	0	38 (77.6)	42 (68.9)										
Time since first symptoms of axSpA , years, mean (SD)	nr-axSpA	6.3 (5.7)	7.5 (3.5)	6.8 (8.5)	12.7 (11.1)	7.3 (7.7)	15.2 (9.0)	7.5 (7.1)	12.1 (10.1)										
	r-axSpA	10.8 (8.2)	12.9 (4.2)	12.5 (9.3)	14.0 (9.3)	13.2 (10.5)	15.3 (0)	12.5 (9.8)	17.6 (12.4)										
ASDAS, mean (SD)	nr-axSpA	3.5 (0.7)	3.2 (0.2)	3.8 (0.8)	3.8 (0.6)	3.7 (0.8)	3.4 (0.1)	3.7 (0.8)	3.9 (0.7)										
	r-axSpA	3.5 (0.8)	3.3 (0.2)	4.0 (0.8)	4.0 (0.6)	3.5 (0.9)	4.4 (0)	3.9 (0.9)	3.9 (0.7)										
BASDAI, mean (SD)	nr-axSpA	6.5 (1.4)	6.1 (0.4)	6.0 (1.1)	7.1 (1.2)	6.7 (1.2)	7.6 (0.7)	6.5 (1.3)	7.4 (1.2)										
	r-axSpA	6.2 (1.4)	6.0 (0.7)	6.7 (1.2)	7.1 (1.2)	6.2 (1.3)	9.2 (0)	6.3 (1.4)	7.0 (1.2)										
hs-CRP (mg/L), geometric mean (geometric CV, %)	nr-axSpA	4.3 (275.8)	2.0 (146.5)	12.6 (96.4)	4.7 (202.7)	5.5 (240.8)	2.1 (290.2)	6.3 (246.5)	3.3 (435.0)										
	r-axSpA	5.7 (183.8)	3.3 (293.1)	10.6 (295.3)	8.4 (167.7)	5.2 (234.0)	5.5 (0)	13.5 (202.9)	5.5 (357.5)										
Prior TNFi exposure , n (%)	nr-axSpA	6 (10.5)	0	1 (6.3)	10 (20.0)	5 (7.9)	0	4 (18.2)	1 (2.7)										
	r-axSpA	6 (9.2)	0	3 (20.0)	8 (28.6)	15 (13.6)	0	12 (24.5)	10 (16.4)										

Safety set. ASDAS <2.1 indicates LDA. Patients randomised to placebo switched to BKZ 160 mg Q4W from Week 16 onwards



Proportion of patients who achieved ASDAS <2.1 and/or BASDAI <4 at Week 52 (NRI)



Randomised set. ASDAS <2.1 indicates LDA. Patients randomised to placebo switched to BKZ 160 mg Q4W from Week 16 onwards

POS1106

